EA200301125A1 - Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы - Google Patents

Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы

Info

Publication number
EA200301125A1
EA200301125A1 EA200301125A EA200301125A EA200301125A1 EA 200301125 A1 EA200301125 A1 EA 200301125A1 EA 200301125 A EA200301125 A EA 200301125A EA 200301125 A EA200301125 A EA 200301125A EA 200301125 A1 EA200301125 A1 EA 200301125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ifn
type
vaccine
related methods
interferon type
Prior art date
Application number
EA200301125A
Other languages
English (en)
Other versions
EA006211B1 (ru
Inventor
Филиппо Беларделли
Джованна Чиавони
Джозеппина Д'Агостино
Энрике Проиетти
Дейвид Ф. Таф
Агнес Ле Бон
Original Assignee
Иституто Супериоре Ди Санита'
Ти Эдвард Дженнер Инститьют Фо Вэксин Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иституто Супериоре Ди Санита', Ти Эдвард Дженнер Инститьют Фо Вэксин Рисерч filed Critical Иституто Супериоре Ди Санита'
Publication of EA200301125A1 publication Critical patent/EA200301125A1/ru
Publication of EA006211B1 publication Critical patent/EA006211B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение касается применения IFN типа I для получения нетоксической композиции адъюванта для усиления гуморального иммунного ответа типа Th-1 на вакцину при защитной иммунизации in vivo, в котором IFN применяется в дозировке, большей или равной 100 000 ЕД/мл на дозу вакцины. Настоящее изобретение также касается набора из частей, включающего нетоксическую композицию адъюванта, содержащую IFN типа I и вакцину, включающую по меньшей мере один антиген, для раздельного, одновременного или последовательного применения при профилактике или лечении заболевания, связанного с присутствием данного антигена.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301125A 2001-04-17 2002-04-16 Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы EA006211B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01830261A EP1250933A1 (en) 2001-04-17 2001-04-17 Vaccines including as an adjuvant high dose type I IFN
PCT/IT2002/000236 WO2002083170A1 (en) 2001-04-17 2002-04-16 Vaccines including as an adjuvant type 1 ifn and processes related thereto

Publications (2)

Publication Number Publication Date
EA200301125A1 true EA200301125A1 (ru) 2004-04-29
EA006211B1 EA006211B1 (ru) 2005-10-27

Family

ID=8184491

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301125A EA006211B1 (ru) 2001-04-17 2002-04-16 Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы

Country Status (13)

Country Link
US (1) US20040146485A1 (ru)
EP (2) EP1250933A1 (ru)
JP (1) JP2004533431A (ru)
KR (1) KR20040022423A (ru)
CN (1) CN100509056C (ru)
AU (1) AU2002309245B2 (ru)
BR (1) BR0208980A (ru)
CA (1) CA2443912A1 (ru)
EA (1) EA006211B1 (ru)
IL (1) IL158440A0 (ru)
MX (1) MXPA03009515A (ru)
NZ (1) NZ529562A (ru)
WO (1) WO2002083170A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
GB2441094B (en) * 2005-05-19 2010-11-03 Edward Jenner Inst For Vaccine Methods for treatment and prevention of infection
US9402917B2 (en) 2009-04-03 2016-08-02 Duke University Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2016179475A1 (en) * 2015-05-07 2016-11-10 Baylor College Of Medicine Dendritic cell immunotherapy
CN107233568A (zh) * 2017-06-20 2017-10-10 上海赛伦生物技术股份有限公司 一种免疫马用的免疫佐剂
WO2022251406A1 (en) * 2021-05-28 2022-12-01 The Regents Of The University Of Michigan Combined agonist adjuvant for coronavirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US6660258B1 (en) * 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
TW586944B (en) * 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
EP1681064A1 (en) * 1999-07-22 2006-07-19 Dainippon Sumitomo Pharma Co., Ltd. Induction of antigen-specific T cells by interferon

Also Published As

Publication number Publication date
IL158440A0 (en) 2004-05-12
US20040146485A1 (en) 2004-07-29
JP2004533431A (ja) 2004-11-04
CN1522154A (zh) 2004-08-18
WO2002083170A1 (en) 2002-10-24
BR0208980A (pt) 2004-12-28
CA2443912A1 (en) 2002-10-24
NZ529562A (en) 2005-09-30
AU2002309245B2 (en) 2008-03-13
MXPA03009515A (es) 2004-12-06
CN100509056C (zh) 2009-07-08
EP1250933A1 (en) 2002-10-23
KR20040022423A (ko) 2004-03-12
EP1381391A1 (en) 2004-01-21
EA006211B1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
NO20010922D0 (no) FremgangsmÕte for DNA vaksinering
NO20015073D0 (no) Vaksiner
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
HUP0401606A2 (hu) West Nile vakcina
NZ547776A (en) Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
IL144671A0 (en) Immunological adjuvants compounds compositions and methods of use thereof
MA27699A1 (fr) Vaccin contre vhc
WO2002032923A3 (en) Improved formulations using heat shock/stress protein-peptide complexes
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
AU2003212170A8 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
JP2009534428A (ja) Ｈｃｖワクチン接種
DE60115051D1 (de) Immunologische adjuvans verbindungen
RU2011105863A (ru) Иммунологическая композиция
CA2114611A1 (en) Method of reversing immunosuppression in vaccines
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
ATE285791T1 (de) Impfstoff, der acemannan als adjuvans enthält
AU2003240790A8 (en) Antibody peg positional isomers, compositions comprising same, and use thereof
EP0952771A4 (en) SAPONIN COMPOSITIONS AND THEIR USE
WO2004100640A3 (en) Marek’s disease virus vaccine
RU2003110420A (ru) Дифференцирование gnrh-i и gnrh-ii

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU